688073 毕得医药
已收盘 07-18 15:00:00
资讯
新帖
简况
毕得医药中标药学院项目 券商积极评价彰显发展潜力
自选股中标信息 · 10:57
毕得医药中标药学院项目 券商积极评价彰显发展潜力
CRO概念盘中跳水,圣诺生物跌0.33%
市场透视 · 07-18 01:48
CRO概念盘中跳水,圣诺生物跌0.33%
毕得医药中标化学学院项目 券商积极评级助力股价上涨
自选股中标信息 · 07-17 10:47
毕得医药中标化学学院项目 券商积极评级助力股价上涨
毕得医药中标化学学院项目 券商积极评级彰显成长潜力
自选股中标信息 · 07-17 10:47
毕得医药中标化学学院项目 券商积极评级彰显成长潜力
上周公募618次调研 乐鑫科技被52家围观
投资快报 · 07-16 22:46
上周公募618次调研 乐鑫科技被52家围观
7月16日毕得医药跌6.06%,泰康医疗健康股票发起A基金重仓该股
证券之星 · 07-16
7月16日毕得医药跌6.06%,泰康医疗健康股票发起A基金重仓该股
上海毕得医药科技股份有限公司发布信息披露管理制度 强化合规与投资者保护
中访网数据 · 07-16
上海毕得医药科技股份有限公司发布信息披露管理制度 强化合规与投资者保护
上海毕得医药科技股份有限公司通过募集资金管理办法,规范资金使用与监管
中访网数据 · 07-16
上海毕得医药科技股份有限公司通过募集资金管理办法,规范资金使用与监管
毕得医药拟续聘中汇会计师事务所为2025年度审计机构
中访网数据 · 07-16
毕得医药拟续聘中汇会计师事务所为2025年度审计机构
毕得医药:7月15日召开董事会会议
每日经济新闻 · 07-15
毕得医药:7月15日召开董事会会议
7月9日毕得医药涨6.07%,泰康医疗健康股票发起A基金重仓该股
证券之星 · 07-09
7月9日毕得医药涨6.07%,泰康医疗健康股票发起A基金重仓该股
毕得医药涨6.07%,开源证券二个月前给出“买入”评级
证券之星 · 07-09
毕得医药涨6.07%,开源证券二个月前给出“买入”评级
CRO指数盘中涨幅扩大至3%,美迪西涨停,昭衍新药、毕得医药、阳光诺和、益诺思跟涨。
金融界 · 07-09
CRO指数盘中涨幅扩大至3%,美迪西涨停,昭衍新药、毕得医药、阳光诺和、益诺思跟涨。
毕得医药涨5.12% 技术壁垒构建成长护城河
智选洞察 · 07-08
毕得医药涨5.12% 技术壁垒构建成长护城河
每周股票复盘:毕得医药(688073)调整回购价格上限并推进股份回购
证券之星 · 07-06
每周股票复盘:毕得医药(688073)调整回购价格上限并推进股份回购
上海毕得医药科技股份有限公司、北京伊诺凯科技有限公司提供化学学院采购商品
DoNews · 07-02
上海毕得医药科技股份有限公司、北京伊诺凯科技有限公司提供化学学院采购商品
毕得医药:已累计回购2.28%股份
格隆汇 · 07-02
毕得医药:已累计回购2.28%股份
上海毕得医药科技股份有限公司中标药学院4-苯并噻唑采购项目
DoNews · 07-01
上海毕得医药科技股份有限公司中标药学院4-苯并噻唑采购项目
中国创新药能否持续让世界买单?券商分析师最新观点
券商中国 · 06-30
中国创新药能否持续让世界买单?券商分析师最新观点
毕得医药早盘放量冲高涨5.06% 资金博弈与估值切换共振加剧
智选洞察 · 06-30
毕得医药早盘放量冲高涨5.06% 资金博弈与估值切换共振加剧
加载更多
公司概况
公司名称:
上海毕得医药科技股份有限公司
所属行业:
研究和试验发展
上市日期:
2022-10-11
主营业务:
上海毕得医药科技股份有限公司的主营业务是为新药研发机构提供专业、高效的药物分子砌块及科学试剂产品及服务。公司的主要产品是分子砌块杂环化合物、分子砌块苯环化合物、分子砌块苯环化合物、催化剂和配体、活性小分子化合物。
发行价格:
88.00
{"stockData":{"symbol":"688073","market":"SH","secType":"STK","nameCN":"毕得医药","latestPrice":60.05,"timestamp":1752822000000,"preClose":60.45,"halted":0,"volume":1015267,"delay":0,"changeRate":-0.0066,"floatShares":43234200,"shares":90882900,"eps":1.3429,"marketStatus":"已收盘","change":-0.4,"latestTime":"07-18 15:00:00","open":61,"high":61,"low":59.72,"amount":61116900,"amplitude":0.0212,"askPrice":60.1,"askSize":10,"bidPrice":60.05,"bidSize":21,"shortable":0,"etf":0,"ttmEps":1.3429,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753061400000},"marketStatusCode":5,"adr":0,"adjPreClose":60.45,"symbolType":"stock_kcb","openAndCloseTimeList":[[1752802200000,1752809400000],[1752814800000,1752822000000]],"highLimit":66.5,"lowLimit":54.41,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":90882948,"isCdr":false,"pbRate":2.68,"roa":"--","peRate":44.716658,"roe":"1.5%","epsLYR":1.32,"committee":0.358025,"marketValue":5458000000,"turnoverRate":0.0235,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2025-07-21。","afterMarket":{"amount":0,"volume":0,"close":60.05,"buyVolume":0,"sellVolume":0,"time":1752824038022,"indexStatus":"已收盘 07-18 15:30:00","preClose":60.45},"floatMarketCap":2596000000},"requestUrl":"/m/hq/s/688073","defaultTab":"news","newsList":[{"id":"2552141176","title":"毕得医药中标药学院项目 券商积极评价彰显发展潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2552141176","media":"自选股中标信息","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552141176?lang=zh_cn&edition=full","pubTime":"2025-07-19 18:57","pubTimestamp":1752922675,"startTime":"0","endTime":"0","summary":"2025年07月19日,据天眼查数据,药学院-2-丙酸显示,中标方为毕得医药,招标方为药学院。近半年内,毕得医药获得4家券商积极评价:开源证券和太平洋证券给予\"买入\"评级。截至发稿,毕得医药股价报60.05元,下跌0.66%,成交额至6111.69万元。中标数据由天眼查提供,由程序或算法识别中标信息页面生成,可能与实际存在差异,不作为决策依据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250719185806a4553825&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250719185806a4553825&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2552690453","title":"CRO概念盘中跳水,圣诺生物跌0.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552690453","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552690453?lang=zh_cn&edition=full","pubTime":"2025-07-18 09:48","pubTimestamp":1752803324,"startTime":"0","endTime":"0","summary":"07月18日,CRO概念盘中跳水,截至09点48分,CRO概念整体指数下跌1.08%,报528.040点。从个股上来看,该概念的成分股中,圣诺生物跌0.33%,凯莱英、皓元医药、毕得医药跌幅居前。从资金上来看,截止发稿,CRO概念主力净流入为-1.91亿,其中药明康德受到资金热捧,主力净流入6846.12万;拉长时间线来看,该板块近20日主力资金净流入-5.81亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718094844a6b0e6a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718094844a6b0e6a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688073","BK0239","BK0216","688117"],"gpt_icon":0},{"id":"2552205483","title":"毕得医药中标化学学院项目 券商积极评级助力股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2552205483","media":"自选股中标信息","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552205483?lang=zh_cn&edition=full","pubTime":"2025-07-17 18:47","pubTimestamp":1752749237,"startTime":"0","endTime":"0","summary":"2025年07月17日,据天眼查数据,化学学院20ml样品瓶盖/顶空瓶盖显示,中标方为毕得医药,招标方为化学学院。近半年内,毕得医药获得4家券商积极评价:太平洋证券和开源证券给予\"买入\"评级。截至发稿,毕得医药股价报60.45元,上涨0.8%,成交额至1.01亿元。中标数据由天眼查提供,由程序或算法识别中标信息页面生成,可能与实际存在差异,不作为决策依据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717184718a450ec49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717184718a450ec49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688073"],"gpt_icon":0},{"id":"2552270483","title":"毕得医药中标化学学院项目 券商积极评级彰显成长潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2552270483","media":"自选股中标信息","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552270483?lang=zh_cn&edition=full","pubTime":"2025-07-17 18:47","pubTimestamp":1752749222,"startTime":"0","endTime":"0","summary":"2025年07月17日,据天眼查数据,化学学院2-氨基间苯二酚显示,中标方为毕得医药,招标方为化学学院。近半年内,毕得医药获得4家券商积极评价:太平洋证券和开源证券给予\"买入\"评级。截至发稿,毕得医药股价报60.45元,上涨0.8%,成交额至1.01亿元。中标数据由天眼查提供,由程序或算法识别中标信息页面生成,可能与实际存在差异,不作为决策依据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717184707a6afa2b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717184707a6afa2b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688073"],"gpt_icon":0},{"id":"2552751371","title":"上周公募618次调研 乐鑫科技被52家围观","url":"https://stock-news.laohu8.com/highlight/detail?id=2552751371","media":"投资快报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552751371?lang=zh_cn&edition=full","pubTime":"2025-07-17 06:46","pubTimestamp":1752705972,"startTime":"0","endTime":"0","summary":"电子行业的乐鑫科技紧随其后,上周以12.54%的涨幅排名第二,其吸引力不容小觑,博时基金、华夏基金等在内的52家公募机构纷纷扎堆对其进行调研。上周有43只个股受到公募机构的积极关注,它们的被调研次数均不少于5次。电子行业被调研103次,被调研个股有11只,涵盖了乐鑫科技、日久光电等涨幅表现较好的个股。此外,华夏基金、嘉实基金和交银施罗德基金上周均以14 次调研并列第三。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717064840a44f7d9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717064840a44f7d9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688686","688018","688690","BK0216","BK0231","688073"],"gpt_icon":0},{"id":"2551922145","title":"7月16日毕得医药跌6.06%,泰康医疗健康股票发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2551922145","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551922145?lang=zh_cn&edition=full","pubTime":"2025-07-16 16:12","pubTimestamp":1752653540,"startTime":"0","endTime":"0","summary":"证券之星消息,7月16日毕得医药跌6.06%,收盘报59.97元,换手率4.97%,成交量2.15万手,成交额1.3亿元。重仓毕得医药的公募基金请见下表:该股最近90天内共有6家机构给出评级,买入评级4家,增持评级2家;过去90天内机构目标均价为52.58。根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为泰康基金的泰康医疗健康股票发起A。该公募基金现任基金经理为傅洪哲。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071600025187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073","159760"],"gpt_icon":0},{"id":"2551118153","title":"上海毕得医药科技股份有限公司发布信息披露管理制度 强化合规与投资者保护","url":"https://stock-news.laohu8.com/highlight/detail?id=2551118153","media":"中访网数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551118153?lang=zh_cn&edition=full","pubTime":"2025-07-16 08:09","pubTimestamp":1752624586,"startTime":"0","endTime":"0","summary":"中访网数据 上海毕得医药科技股份有限公司近日审议通过《信息披露管理制度》,进一步规范公司及相关信息披露义务人的信息披露行为,加强信息披露事务管理,保护投资者合法权益。自愿披露信息需与法定披露一致,不得影响股价或操纵市场。控股股东或实际控制人需配合履行披露义务。毕得医药表示,该制度旨在提升公司治理透明度,防范内幕交易风险,维护投资者权益,同时为科创板上市公司信息披露合规性提供操作指引。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507160812149544186e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507160812149544186e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2551611815","title":"上海毕得医药科技股份有限公司通过募集资金管理办法,规范资金使用与监管","url":"https://stock-news.laohu8.com/highlight/detail?id=2551611815","media":"中访网数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551611815?lang=zh_cn&edition=full","pubTime":"2025-07-16 08:09","pubTimestamp":1752624585,"startTime":"0","endTime":"0","summary":"中访网数据 上海毕得医药科技股份有限公司近日审议通过了《募集资金管理办法》,旨在规范公司募集资金的存储、使用及监管,确保资金安全并提高使用效益。公司需设立专项账户存放募集资金,并在资金到账后1个月内与保荐机构、商业银行签订三方监管协议。此外,毕得医药强调,控股股东、实际控制人及关联方不得占用募集资金。保荐机构需履行持续督导职责,年度审计时会计师事务所需出具鉴证报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507160812149544186c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507160812149544186c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2551118381","title":"毕得医药拟续聘中汇会计师事务所为2025年度审计机构","url":"https://stock-news.laohu8.com/highlight/detail?id=2551118381","media":"中访网数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551118381?lang=zh_cn&edition=full","pubTime":"2025-07-16 08:09","pubTimestamp":1752624577,"startTime":"0","endTime":"0","summary":"中访网数据 上海毕得医药科技股份有限公司于2025年7月15日召开董事会及监事会会议,审议通过续聘中汇会计师事务所为公司2025年度财务报告及内部控制审计机构的议案,该事项尚需提交股东大会审议。中汇会计师事务所具备丰富的证券业务经验,2024年审计收入达10.14亿元,其中证券业务收入4.56亿元,服务上市公司205家。此次续聘需经股东大会批准后生效,预计对公司财务及内控审计工作的连续性无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071608115197a7ae4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071608115197a7ae4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2551161130","title":"毕得医药:7月15日召开董事会会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2551161130","media":"每日经济新闻","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551161130?lang=zh_cn&edition=full","pubTime":"2025-07-15 18:59","pubTimestamp":1752577174,"startTime":"0","endTime":"0","summary":"每经AI快讯,毕得医药(SH 688073,收盘价:63.84元)7月15日晚间发布公告称,公司第二届第二十三次董事会会议于2025年7月15日在公司会议室召开。会议审议了《关于续聘公司2025年度审计机构的议案》等文件。2024年1至12月份,毕得医药的营业收入构成为:研究和试验发展行业占比100.0%。截至发稿,毕得医药市值为58亿元。每经头条(nbdtoutiao)——美国男童误食电池,出口企业以2.87亿元和解,保险公司赔一半!法律专家:天价赔偿可能导致破产,中企出海保险要买够(记者 曾健辉)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071519005997a6f1ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071519005997a6f1ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2550811306","title":"7月9日毕得医药涨6.07%,泰康医疗健康股票发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2550811306","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550811306?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:12","pubTimestamp":1752048768,"startTime":"0","endTime":"0","summary":"证券之星消息,7月9日毕得医药涨6.07%,收盘报60.1元,换手率6.37%,成交量2.76万手,成交额1.64亿元。重仓毕得医药的公募基金请见下表:该股最近90天内共有6家机构给出评级,买入评级4家,增持评级2家;过去90天内机构目标均价为52.58。根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为泰康基金的泰康医疗健康股票发起A。该公募基金现任基金经理为傅洪哲。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070900025416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159760","BK0216","688073"],"gpt_icon":0},{"id":"2550112681","title":"毕得医药涨6.07%,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2550112681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550112681?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:12","pubTimestamp":1752048758,"startTime":"0","endTime":"0","summary":"今日毕得医药(688073)涨6.07%,收盘报60.1元。2025年4月24日,开源证券研究员余汝意,聂媛媛发布了对毕得医药的研报《公司信息更新报告:公司收入利润均加速增长,盈利能力持续改善》,该研报对毕得医药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为79.61%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为华创证券的万梦蝶。毕得医药(688073)个股概况:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070900025412.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","161027"],"gpt_icon":0},{"id":"2550506101","title":"CRO指数盘中涨幅扩大至3%,美迪西涨停,昭衍新药、毕得医药、阳光诺和、益诺思跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2550506101","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550506101?lang=zh_cn&edition=full","pubTime":"2025-07-09 11:05","pubTimestamp":1752030351,"startTime":"0","endTime":"0","summary":"CRO指数盘中涨幅扩大至3%,美迪西涨停,昭衍新药、毕得医药、阳光诺和、益诺思跟涨。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/09110551578183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688710","BK1141","688621","688202","603127","06127","BK0216","688073","BK1576"],"gpt_icon":0},{"id":"2549567717","title":"毕得医药涨5.12% 技术壁垒构建成长护城河","url":"https://stock-news.laohu8.com/highlight/detail?id=2549567717","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549567717?lang=zh_cn&edition=full","pubTime":"2025-07-08 09:39","pubTimestamp":1751938793,"startTime":"0","endTime":"0","summary":"毕得医药股价大幅上涨,最新价58.14元,涨跌幅为5.12%。截至7月7日,主力资金连续两日净流出591.2万元,反映出市场对创新药政策窗口期的谨慎情绪。公司55.89%的境外收入结构,叠加国际医药投融资周期波动,进一步加剧短期资金分歧。技术壁垒构建成长护城河毕得医药长期发展动能与CRO行业高景气度深度绑定。2024年报显示其分子砌块业务收入占比超84%,核心产品技术壁垒形成差异化竞争优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708093958a69bf952&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708093958a69bf952&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2549932816","title":"每周股票复盘:毕得医药(688073)调整回购价格上限并推进股份回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2549932816","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549932816?lang=zh_cn&edition=full","pubTime":"2025-07-06 08:00","pubTimestamp":1751760040,"startTime":"0","endTime":"0","summary":"截至2025年7月4日收盘,毕得医药报收于55.8元,较上周的51.36元上涨8.64%。本周,毕得医药7月3日盘中最高价报61.5元。6月30日盘中最低价报50.2元。毕得医药当前最新总市值50.71亿元,在医疗服务板块市值排名30/50,在两市A股市值排名2956/5149。本周关注点公司公告汇总:毕得医药调整回购价格上限至不超过人民币71.44元/股。公司公告汇总:毕得医药累计已回购股份2072148股,占总股本比例2.28%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070600001163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2548581055","title":"上海毕得医药科技股份有限公司、北京伊诺凯科技有限公司提供化学学院采购商品","url":"https://stock-news.laohu8.com/highlight/detail?id=2548581055","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548581055?lang=zh_cn&edition=full","pubTime":"2025-07-03 03:50","pubTimestamp":1751485803,"startTime":"0","endTime":"0","summary":"天眼查App显示,2025年07月01日,化学学院发布招标公告,采购乙烯基硼酸频哪醇酯等实验用品。本次采购由上海毕得医药科技股份有限公司和北京伊诺凯科技有限公司分别作为供应商,提供相关商品。总价分别为29.4元人民币和22.4元人民币。采购类型为线上单,经费负责人审批时间为2025年07月01日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507030351159797a68d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507030351159797a68d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2548893280","title":"毕得医药:已累计回购2.28%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2548893280","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548893280?lang=zh_cn&edition=full","pubTime":"2025-07-02 17:47","pubTimestamp":1751449654,"startTime":"0","endTime":"0","summary":"格隆汇7月2日丨毕得医药(688073.SH)公布,截至2025年6月30日,公司通过集中竞价交易方式已累计回购股份2,072,148股,占公司总股本的2.28%,回购成交的最高价为53.30元/股,最低价为37.47元/股,支付的资金总额为人民币94,147,819.45元(不含印花税、交易佣金等交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507021747439533c27e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507021747439533c27e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0216","688073"],"gpt_icon":0},{"id":"2548608882","title":"上海毕得医药科技股份有限公司中标药学院4-苯并噻唑采购项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2548608882","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548608882?lang=zh_cn&edition=full","pubTime":"2025-07-02 03:48","pubTimestamp":1751399283,"startTime":"0","endTime":"0","summary":"天眼查App显示,2025年06月30日,药学院完成一项采购项目,标的为4-苯并噻唑。根据发布的中标结果显示,本次采购的供应商为上海毕得医药科技股份有限公司,中标金额为87.5元人民币。公告类型为中标结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507020349119532f0c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507020349119532f0c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688073","BK0216"],"gpt_icon":0},{"id":"2547015164","title":"中国创新药能否持续让世界买单?券商分析师最新观点","url":"https://stock-news.laohu8.com/highlight/detail?id=2547015164","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547015164?lang=zh_cn&edition=full","pubTime":"2025-06-30 23:29","pubTimestamp":1751297340,"startTime":"0","endTime":"0","summary":"医药魔方统计,2025年1—5月,中国创新药企对外授权交易总金额已达455亿美元,超过2024年上半年的交易总额,创新药出海授权交易大爆发。亮眼数据的背后,是中国创新药整体水平的强势崛起。“中国创新药产业的研发、临床与生产能力,正处于与国际一线水平接轨的初始阶段。”由于BD数据不及预期,年内大涨明显的创新药企业荣昌生物股价近期大幅回调,从而带动创新药板块整体调整。华泰柏瑞恒生创新药ETF6月中旬以来一度单周下行超过8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630233154a7267585&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630233154a7267585&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","688177","688181","603087","600535","600267","603567","603259","600998","600332","601089","600645","603367","600080","603716","600867","688513","601607","600216","603127","688278","600513","603590","BK0239","600774","688488","688336","06160","603456","688506","600682","600079","600200","600056","688136","688202","688198","603998","688235","688131","688073","688117","600062","688166","688331","600380","600851","600351","605199","688317","688068","688091","688505","688520","600789","688222","688163","688189","688356","603229","603707","600572","600881","600422","600420","600521","600721","600196","688321","159992","600276","688319","600222","600557"],"gpt_icon":0},{"id":"2547032016","title":"毕得医药早盘放量冲高涨5.06% 资金博弈与估值切换共振加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2547032016","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547032016?lang=zh_cn&edition=full","pubTime":"2025-06-30 10:26","pubTimestamp":1751250417,"startTime":"0","endTime":"0","summary":"毕得医药早盘股价大幅上涨,截至10点26分,公司股价报53.96元/股,上涨5.06%,创近3个月新高。市场成交额达5627万元,换手率2.47%,振幅7.32%,呈现放量冲高走势。资金博弈与估值切换共振毕得医药近期净流入主要受资金面波动与板块轮动影响。医疗服务板块6月26日单日主力净流出6.96亿元,药明康德等权重股下跌引发情绪传导,导致盘中振幅扩大至3.96%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630102659a724fa52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630102659a724fa52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688073","BK0216"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752964008608,"stockEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.2653},{"period":"3month","weight":0.6192},{"period":"6month","weight":0.2628},{"period":"1year","weight":1.0198},{"period":"ytd","weight":0.2453}],"compareEarnings":[{"period":"1week","weight":0.0069},{"period":"1month","weight":0.043},{"period":"3month","weight":0.0787},{"period":"6month","weight":0.0903},{"period":"1year","weight":0.1872},{"period":"ytd","weight":0.0545}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海毕得医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"3610人(较上一季度增加6.55%)","perCapita":"11976股","listingDate":"2022-10-11","address":"上海市杨浦区翔殷路128号11号楼A座101室","registeredCapital":"9088万元","survey":" 上海毕得医药科技股份有限公司的主营业务是为新药研发机构提供专业、高效的药物分子砌块及科学试剂产品及服务。公司的主要产品是分子砌块杂环化合物、分子砌块苯环化合物、分子砌块苯环化合物、催化剂和配体、活性小分子化合物。","listedPrice":88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"毕得医药(688073)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供毕得医药(688073)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"毕得医药,688073,毕得医药股票,毕得医药股票老虎,毕得医药股票老虎国际,毕得医药行情,毕得医药股票行情,毕得医药股价,毕得医药股市,毕得医药股票价格,毕得医药股票交易,毕得医药股票购买,毕得医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"毕得医药(688073)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供毕得医药(688073)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}